№2_2022

ONCOLOGY
BULLETIN
OF THE VOLGA REGION Vol. 13, no. 2. 2022
J. Natl. Cancer Inst.— 1999. — 91. — P. 1310-16.
doi: 10.1093/jnci/91.15.1310.
14. Leongamornlert D., Mahmud N.,
Tymrakiewicz M., et al. Germline BRCA1
mutations increase prostate cancer risk //
Br. J. Cancer. — 2012. — 106. — P. 1697-701.
doi: 10.1038/bjc.2012.146.
15. Tischkowitz M., Sabbaghian N., Ray A.M., et al.
Analysis of the gene coding for the BRCA2-
interacting protein PALB2 in hereditary prostate
cancer // Prostate. — 2008. — 68. — P. 675-8.
doi: 10.1002/pros.20729.
16. Dansonka-Mieszkowska A., Kluska A.,
Moes J., et al. A novel germline PALB2 deletion
in Polish breast and ovarian cancer
patients // BMC Med. Genet. — 2010. — 11. — 20.
doi: 10.1186/1471-2350-11-20.
17. Teo Z.L., Park D.J., Provenzano E., et al.
Prevalence of PALB2 mutations in Australasian
multiple-case breast cancer families //
Breast Cancer Res. — 2013. —15. — R17.
doi: 10.1186/bcr3392.
18. Tominaga K., Morisaki H., Kaneko Y., et al.
Role of human Cds1 (Chk2) kinase in DNA damage
checkpoint and its regulation by p53 // J. Biol.
Chem. — 1999. — 274. — P. 31463-31467.
doi: 10.1056/NEJMoa1113260.
19. Ahn J., Urist M., Prives C. The Chk2 protein kinase //
DNA Repair. — 2004. — 3. — P. 1039-1047.
doi: 10.1016/j.dnarep.2004.03.033.
20. Staalesen V., Falck J., Geisler S., et al.
Alternative splicing and mutation status of CHEK2
in stage III breast cancer // Oncogene. — 2004.
doi: 10.1038/sj.onc.1207928.
21. Matsui T., Katsuno Y., Inoue T., et al. Negative
regulation of Chk2 expression by p53 is
dependent on the CCAAT-binding transcription
factor NF-Y // J. Biol. Chem. — 2004. — 279. —
P. 25093-25100. doi: 10.1074/jbc.M403232200.
22. Munch C., Kirsch S., Fernandes A.M., et al.
Evolutionary analysis of the highly dynamic
CHEK2 duplicon in anthropoids //
BMC Evol.Biol. — 2008. — 8. — 269.
doi: 10.1186/1471-2148-8-269.
23. Li J., Williams B.L., Haire L.F., et al. Structural and
functional versatility of the FHA domain in DNAdamage
signaling by the tumor suppressor kinase
Chk2 // Mol. Cell. — 2002. — 9. — P. 1045-1054.
doi: 10.1016/s1097-2765(02)00527-0.
24. Cai Z., Chehab N.H., Pavletich N.P. Structure and
activation mechanism of the CHK2 DNA damage
checkpoint kinase // Mol. Cell. — 2009. — 35. — P.
818-829. doi: 10.1016/j.molcel.2009.09.007.
25. Wybenga-Groot L.E., Ho C.S., Sweeney F.D., et al.
Structural basis of Rad53 kinase activation by
dimerization and activation segment exchange //
Cell Signal. — 2014. — 26. — P. 1825-1836.
doi: 10.1016/j.cellsig.2014.05.004.
26. Southey M.C., Goldgar D.E., Winqvist R., et al.
PALB2, CHEK2 and ATM rare variants and
cancer risk: data from COGS // J. Med. Genet. —
2016, Dec. — 53 (12). — P. 800-811.
doi: 10.1136/jmedgenet-2016-103839.
27. Bell D.W., Varley J.M., Szydlo T.E., et al.
Heterozygous germ line hCHK2 mutations in
Li-Fraumeni syndrome // Science. — 1999. — 286.
— P. 2528-2531. doi:10.1126/science.286.
5449.2528.
28. Wu X., Webster S.R., Chen J. Characterization
of tumor-associated Chk2 mutations //
J. Biol. Chem. — 2001. — 276. — P. 2971-2974.
doi: 10.1074/jbc.M009727200.
29. Allinen M., Huusko P., Mantyniemi S., et al.
Mutation analysis of the CHK2 gene in
families with hereditary breast cancer //
Br. J. Cancer. — 2001. — 85. — P. 209-212.
doi: 10.1054/bjoc.2001.1858.
30. Nummela P., Saarinen L., Thiel A., et al.
Genomic profile of pseudomyxoma peritonei
analyzed using next-generation sequencing
and immunohistochemistry // Int. J. Cancer.
— 2015, Mar 1. — 136(5). — P. E282-9.
doi: 10.1002/ijc.29245.
31. Barnetson R.A., Tenesa A., Farrington S.M.,
et al. Identification and survival of carriers
of mutations in DNA mismatch-repair
genes in colon cancer // N. Engl. J. Med.
— 2006. — 354 (26). —
P. 2751-2763. PubMedGoogle Scholar Crossref.
32. Hampel H., Frankel W.L., Martin E., et al.
Feasibility of screening for Lynch syndrome
among patients with colorectal cancer //
J. Clin. Oncol. — 2008, Dec 10. — 26 (35). —
P. 5783-8. doi: 10.1200/JCO.2008.17.5950.
33. Pearlman R., Frankel W.L., Swanson B., et al.;
Ohio Colorectal Cancer Prevention Initiative
Study Group. Prevalence and Spectrum
of Germline Cancer Susceptibility Gene
Mutations Among Patients With Early-
Onset Colorectal Cancer // JAMA Oncol.
— 2017 Apr 1. — 3 (4). — P. 464-471
doi: 10.1001/jamaoncol.2016.5194.
Clinical case 73